CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2016 Genitourinary Cancers Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Pal on Biomarker Development in Renal Cell Carcinoma
Dr. Crawford on Ongoing Research With Radium-223 in mCRPC
Dr. Stock on the Optimal Use of Radium-223 in mCRPC
Oncology Conference Articles
Novel Bladder Cancer Strategies Target PD-1/PD-L1 and VEGF Pathways
Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.
Gomella Discusses Radium-223 Impact in mCRPC
Leonard Gomella, MD, discusses the optimal patient population to receive radium-223 for prostate cancer and how oncologists should best use it.
Questions Loom Over Androgen-Targeting Strategies in Metastatic Prostate Cancer
Targeting androgen receptor signaling with recently approved agents has improved outcomes for men with metastatic castration-resistant prostate cancer but significant questions linger about how to tackle resistance to the therapies.
Oral HDAC Inhibitor Improves Antitumor Activity of IL-2 in mRCC
A selective class I oral histone deactylase inhibitor may increase the antitumor effect of high- dose interleukin-2 in renal cell carcinoma.
Nivolumab's Survival Benefit Sustained Across RCC Subgroups
Nivolumabâ€™s second-line survival benefit in renal cell carcinoma was consistent across subgroups categorized by patient risk status, prior treatment, and degree of metastases, according to an update of the phase III CheckMate-025 trial.
Hypofractionated Radiotherapy May Be New Standard of Care in Prostate Cancer
Hypofractionated radiotherapy demonstrated similar toxicity and was noninferior to standard radiation therapy for preventing PSA increases or disease recurrences for men with intermediate-risk prostate cancer.
Atezolizumab Update Affirms Activity in Bladder Cancer
Second-line treatment with atezolizumab (MPDL3280A) led to durable responses in patients with locally advanced or metastatic urothelial carcinoma.
Combo of Celecoxib and Zoledronic Acid Improves Survival in Metastatic Prostate Cancer
Adding celecoxib and zoledronic acid to standard treatment extended survival in men with metastatic prostate cancer commencing first-line hormone therapy, according to updated data from the STAMPEDE trial.
First Checkpoint/Chemo Combo Study for Urothelial Cancer Falls Short
The addition of the CTLA-4 inhibitor ipilimumab to cisplatin and gemcitabine did not significantly improve overall survival for patients with metastatic urothelial cancer.
Avelumab Spurs Responses in Refractory Metastatic Urothelial Cancer
The investigational anti-PD-L1 antibody avelumab demonstrated antitumor activity with an acceptable safety profile in a phase Ib trial of patients with metastatic urothelial cancer refractory to standard therapy.
Docetaxel First Choice After Abiraterone in 50% of Patients with mCRPC
A post hoc analysis of the COU-AA-302 clinical trial suggests that docetaxel has antitumor activity as first subsequent therapy following disease progression with abiraterone acetate in men with chemotherapy-naÃ¯ve, metastatic castration-resistant prostate cancer.
Can Aspirin Avert Lethal Prostate Cancer? Long-term Study Suggests a Possible Role
Aspirinâ€™s benefits may now extend to reducing the risk of deadly prostate cancer, according to the results of an observational study which found that previously undiagnosed men who took regular aspirin had a 24% lower risk of developing a lethal form of the disease.
Liquid Biopsy Paves Way for Personalized Selection Tool in Prostate Cancer
The non-invasive liquid biopsy, if validated, could lead to the development of a personalized selection tool in men with advanced prostate cancer.
Cabozantinib Improves PFS Across High-Risk RCC Subgroups
Cabozantinib significantly improved progression-free survival versus everolimus in patients with renal cell carcinoma regardless of the degree of metastases, type or number of prior treatments, or patient risk status.
EGFR TKIs in the Adjuvant Setting in NSCLC
Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel Improves OS in Nonsquamous NSCLC
Neoadjuvant Nivolumab Plus Ipilimumab Active in dMMR Early-Stage Colon Cancer
Atezolizumab Plus Bevacizumab Shows Durable Activity in Advanced HCC
Olaparib Substantially Improves PFS as Frontline Maintenance in Ovarian Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.